Skip to content

Pediatric Optimal Tuberculosis Treatment Evaluation and Reassessment

Pediatric Optimal Tuberculosis Treatment Evaluation and Reassessment

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07357844
Acronym
POTTER
Enrollment
150
Registered
2026-01-22
Start date
2025-01-03
Completion date
2026-12-31
Last updated
2026-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis Disease

Keywords

Tuberculosis, Children

Brief summary

The treatment of tuberculosis disease in children benefits from clear and up-to-date recommendations from the World Health organization. The research issues supported by the WHO mainly concern tuberculosis treatment implementation in areas of high incidence and low economic level. Pediatric cohorts in countries with high economic levels are rare, making it impossible to quantify and describe deviations from optimal recommendations. The French recommendations are mainly focused on screening cases of tuberculosis, without specific guidelines for care organization and recent practice evaluation. The retrospective study of patients followed by the pediatric infectious disease team of the Hospices Civils de Lyon (HCL) would allow to quantify treatment successes and failures, and to describe these failures in a French pediatric tertiary care center. This retrospective analysis is part of an evolution of the pediatric infectious diseases' activity of HCL in 2024: structuring of the service with a full-time practitioner, establishment of multi-professional care with the involvement of psychologists and clinical pharmacists. This retrospective study will help to understand the causes of failure in French tertiary pediatric centers and to describe the expected benefits of a structured and multi-professional care to improve the treatment of pediatric tuberculosis diseases in France.

Interventions

None listed

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No

Inclusion criteria

: \- Patients under 18 years old, with tuberculosis disease confirmed from patient's clinical file

Exclusion criteria

: * Tuberculosis disease ruled out from patient's clinical file * Parental opposition or patient opposition (if over 18 years old)

Design outcomes

Primary

MeasureTime frameDescription
Tuberculosis treatment outcome2014-2024Tuberculosis treatment outcome, per World Health organization definitions: failed, cured, completed, died, lost to follow-up, not evaluated, success

Secondary

MeasureTime frameDescription
Secondary outcomes2024-2026Compliance with anti-tuberculosis treatment
Secondary outcomes:2024-2026Compliance with follow-up consultations

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026